
ConcertAI Launches New Generative and Agentic AI-Powered Precision Suite™ Accelerating Oncology Insights and Actions for Healthcare and Life Sciences
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ConcertAI, a leader in oncology-focused generative and agentic AI solutions, today announced the launch of its new Precision Suite™. This groundbreaking family of AI-powered solutions redefines the way life sciences and healthcare organizations achieve actionable insights, optimize clinical trials, accelerate in-market execution, and drive improved patient outcomes while saving millions in cost. Powered by ConcertAI's proprietary CARAai™ platform and the unparalleled depth of its integrated Oncology Data, the Precision Suite delivers rapid, persona-tailored insights and enterprise-wide value.
The Precision Suite leverages CARAai's multi-modal, AI-curated data architecture to translate complex medical and genomic data into precise, real-world applications. These applications are built on a unique platform that is comprised of assistants, agents, LLMs and LRMs that are specifically designed and trained to support use cases in life sciences and healthcare. Its seamless integration of diverse data types enables life sciences teams to respond faster, make evidence-backed decisions, and maximize strategic impact. At launch, the suite includes three powerful applications tailored to distinct use cases across the healthcare ecosystem.
Precision Explorer™ empowers Health Economics and Outcomes Research (HEOR), epidemiology, and medical teams to uncover actionable insights within minutes. Generative AI and intuitive interfaces streamline cohort creation, outcomes analysis, and hypothesis testing, unlocking insights 2x faster than traditional methods, saving customers millions. With its ability to leverage curated oncology data and align with industry guidelines, such as ASCO® Standards, Precision Explorer ensures high-quality, citation-backed results.
Precision Trials™ transforms clinical trial operations by enabling smarter, faster decisions in study design, site selection, and patient recruitment. Powered by dynamic AI agents, this solution reduces costly trial amendments, improves site performance, and ensures diversity and enrollment goals are met. CARAai's advanced data-processing capabilities provide real-time assessments, shortening trial timelines with the potential to deliver $4M+ in cost savings for Phase II and III studies.
Precision GTM™ focuses on commercialization strategies for oncology therapies, unifying fragmented clinical, claims, and social determinants of health data. Harnessing CARAai's multi-modal insights, this platform enables brand teams to track the real-time standard of care, physician trends, and treatment pathways. By accelerating decision-making and enabling timely engagement, Precision GTM empowers teams to achieve faster, more impactful market execution while generating up to $7M in value for a typical oncology brand.
Precision360™, the backbone of ConcertAI's Precision Suite™, integrates EMR and genomic data alongside claims and social determinants of health information to create a revolutionary new RWD dataset. With AI-curation and a recency of less than a week, it provides real-time access to actionable insights, eliminating delays in oncology research and decisions. Designed for speed and efficiency, Precision360 provides accuracy and reliability, even in complex, unstructured datasets.
'Precision Suite is a testament to our commitment to innovation and patient-first outcomes,' said Eron Kelly, CEO of ConcertAI. 'Its ability to process complex, diverse datasets in near real-time has allowed us to deliver immediately actionable insights that will save customers millions in costs, while accelerating their time to market for life saving therapeutics. These new SaaS products are all built on our CARAai platform, the leading agentic AI platform built specifically for the needs of the life sciences enterprise.'
'ConcertAI serves 75% of the top life science companies and more than 50% of the largest global healthcare providers,' said Jeff Elton, Ph.D., Vice Chairman of ConcertAI. 'This launch signifies the evolution of ConcertAI from providing specialized solutions to delivering enterprise-class SaaS tools. Precision Suite aligns our expertise with our mission to deliver scalable, impactful solutions that redefine what's possible in life sciences and healthcare today.'
Precision Explorer™ and Precision Trials™ will be available beginning June 30, 2025. Precision GTM™ will follow with availability by July 31, 2025. With these solutions, ConcertAI solidifies its position as the leader in generative and agentic AI tailored for oncology and broader life sciences applications.
About ConcertAI:
ConcertAI is the leader in predictive and generative AI SaaS and real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai™ technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers, and medical societies. TeraRecon provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT. CancerLinQ® is an initiative of ConcertAI, providing oncology providers with ASCO-aligned automated QOPI and ASCO Certified® quality solutions and SmartLinQ™ analytic services. Headquartered in Cambridge, Massachusetts, ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. For more information, visit us at concertai.com.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
28bio Announces Nexon™ Neurotechnology Platform Powered by Engineered Human Brains
Exhibits complex neurological processes—including memory, learning, and cognition—and predicts human outcomes in preclinical drug development NEW ORLEANS, June 9, 2025 /PRNewswire/ -- 28bio today announced the Nexon™ neurotechnology platform—a major advancement in understanding human brain function. The platform integrates tissue engineering, neural interfacing and AI to engineer human brains at-scale and replicate complex neurological processes. The Nexon™ platform is now being used to improve the prediction of therapeutic efficacy and toxicity in humans, with several of the world's largest pharma companies already integrating Nexon™ into their drug development workflows. The Nexon™ platform also incorporates Organoid Intelligence (OI). The growing field of OI combines human brain organoids with brain-machine interfaces to model memory, learning, and cognition in vitro, offering novel functional cognitive biomarkers with the potential to reshape drug development in neurodegenerative disorders including Alzheimer's disease. Neurological drug development faces some of the highest failure rates in the pharmaceutical industry, due to poor translatability of animal models. Despite promising preclinical study results, many therapies ultimately fail in humans—contributing to a growing neurological health crisis and need for more predictive, human-relevant models. "We engineer human brains capable of elucidating the complexity of neurological processes and produce predictive data needed to change the trajectory of neurological drug development," said Alif Saleh, CEO of 28bio. "Industry and regulators are urgently asking for solutions to develop better neurological drugs faster and cheaper." About 28bio28bio is a neurotechnology company engineering human brains at-scale exhibiting memory, learning, and cognitive functions. Its Nexon™ platform integrates tissue engineering, neural interfacing, and AI to reverse today's neurological health crisis by improving the ability to predict which therapies will work in humans. 28bio is committed to advancing ethical standards in the development of brain organoid technology and engineered human cognition. For more information, visit View original content to download multimedia: SOURCE 28bio Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data


Business Wire
2 hours ago
- Business Wire
'AI-First' Hype Gives Way to Reality: New Speechmatics Report Reveals What's Actually Working in AI
CAMBRIDGE, UK--(BUSINESS WIRE)--After a wave of bold 'AI-first' announcements from major tech players, many are now scaling back. Rather than betting on speculative demos, successful enterprises are treating Voice AI as critical infrastructure. Share As the AI gold rush slows, a new report from Speechmatics explores what's actually working — and where the real value lies. Titled The Voice AI Reality Check: Frontline Perspectives for Enterprise in 2025, the report zeroes in on one of the fastest-evolving areas of AI: Voice AI. Built on interviews with leaders across healthcare, compliance, media, public services, and research, it reveals a clear shift from flashy demos to embedded, operational AI — where tools assist humans, deliver measurable ROI, and quietly power core infrastructure. Report highlights include: Assistive over autonomous: The most effective deployments augment people rather than replace them. Assistive agents are driving real ROI. Multilingual as standard: Real-time code-switching is now a baseline requirement, not a bonus. Accuracy is make-or-break: With growing global concerns over AI hallucinations, precision is essential — especially in compliance-heavy environments. Voice as infrastructure: Quietly embedded tools are outperforming headline-grabbing features. Rather than betting on speculative demos, successful enterprises are treating Voice AI as critical infrastructure. It's being embedded into workflows that demand speed, accuracy, and trust — from noisy control rooms to multilingual contact centres. The report closes with future-looking predictions, outlining the rise of emotionally intelligent, adaptive, and natively multilingual voice systems — and offers guidance on what enterprises must prioritise next.


Business Wire
3 hours ago
- Business Wire
FIA President Mohammed Ben Sulayem Looking Forward to Visiting ‘Iconic' Macau for the 2025 FIA Annual Conference
MACAU--(BUSINESS WIRE)--The Fédération Internationale de l'Automobile (FIA), the global governing body for motorsport and the federation for mobility organisations worldwide, will shortly be in Macau for the 2025 FIA Extraordinary General Assembly and Annual Conference. Marking the first time this event has ever taken place in this diverse region, the conference will be hosted in partnership with the Automobile General Association Macao-China (AAMC) and Galaxy Entertainment Group and held at the Galaxy International Convention Centre. The event will welcome over 500 senior FIA delegates across mobility and motorsport from 149 countries, offering the opportunity to address key initiatives in road safety, sustainable mobility, regional sporting growth, and innovation in transport, with the FIA President Mohammed Ben Sulayem in attendance. Speaking ahead of his visit to Macau, FIA President Mohammed Ben Sulayem said: 'Global gatherings like this are vital to the health of our federation. Bringing our community together allows us an invaluable opportunity for engagement and participation, particularly within a pivotal election year. 'The Members of the FIA are at the heart of everything we do, and I am looking forward to being inspired by and connected to them over the next few days, strengthening the link between sport and mobility, expanding our reach, and continuing to impact the global stage. 'I am incredibly proud of the progress we have made together during my first term in office and look forward to continuing that partnership going forward. I am committed to the transformation of the FIA, so it can be an even more positive force for society. Globally, we remain committed to growing motorsport participation through grassroots initiatives and accessibility programmes such as the Affordable Cross Car and the Global Karting Plan. 'At the same time, we continue to empower all regions through our mobility capabilities, maintaining a central role in the automotive industry and leading the dialogue on the future of sustainable cities, safety, and transport.' Commenting on the location of this year's conference, Ben Sulayem said: 'Macau is iconic within the world of motorsport and a fitting location for the FIA to host one of the most important weeks of our calendar. I look forward to seeing much of what this unique destination has to offer.' The conference follows the FIA's recent announcement regarding the FIA's significant financial turnaround and strongest results in almost ten years. Reporting a profit of €4.7m, and an operating income of €182m for 2024, this puts the FIA back in the black following the inheritance of a €-24.0m deficit in 2021 from the previous administration. The conference will be attended by representatives from the 245 FIA Member Clubs. This structure forms the backbone of the federation's governance and operations, with each full Member Club holding voting rights across the FIA's elections and regulatory decisions. Clubs are grouped into two primary categories, with some serving in both roles: Mobility Clubs – provide mobility services and represent the interest of road users, with a focus on road safety, travel and tourism, consumer rights, and sustainable mobility National Sporting Authorities (ASNs) – govern and develop motorsport at a national level, are responsible for sporting events, issuing licenses, and engagement across regulations The Fédération Internationale de l'Automobile (FIA) is the governing body for world motor sport and the federation for mobility organisations globally. It is a non-profit organisation committed to driving innovation and championing safety, sustainability and equality across motor sport and mobility. Founded in 1904, with offices in Paris, London and Geneva, the FIA brings together 245 Member Organisations across five continents, representing millions of road users, motor sport professionals and volunteers. It develops and enforces regulations for motor sport, including seven FIA World Championships, to ensure worldwide competitions are safe and fair for all. The 2025 FIA Conference is hosted in association with Galaxy Entertainment Group and will be held at the International Convention Centre from 10-12 June. The Galaxy International Convention Centre is situated within the Galaxy Macau Integrated Resort which regularly plays host to world class sporting and conference events, and international exhibitions.